The OF·27 clinical assessment is a twelve-week, single-blind, vehicle-controlled trichoscopy study conducted by Abich, an independent testing laboratory, under reference REL/0504/2026, in forty participants.
The design follows the logic of the preceding notes. Density was measured by trichoscopy (Note 08). The study was vehicle-controlled, meaning the formulation was compared against an identical base without the active proteins, which isolates the contribution of the oleosome-bound FGF-7 and FGF-2 from the base itself. It was single-blind, meaning participants did not know which they had received. It ran for twelve weeks, a span chosen to fall within the follicle's growth phase. The sample was forty participants, divided equally between the active formulation and the vehicle.
At twelve weeks, terminal hair density in the active group was measured 33.5% above its own baseline, a difference reported as statistically significant (p<0.0001). In the vehicle group the same measure was 7.2% above baseline, a change that did not reach significance. Secondary measures in the active group recorded a 17.0% rise in the anagen-to-telogen ratio, a 10.6% rise in mean shaft diameter (p=0.0027), a 22.2% rise in scalp hydration, and a 27.2% reduction in transepidermal water loss, each against baseline.
The study has the limits of its design, and naming them is part of the record. Forty participants is a defined sample, not a large population. Twelve weeks covers part of the growth cycle, not its full length. A single-blind, vehicle-controlled design controls for the base and for participant expectation but is not a multi-centre trial. The figures above describe what was measured under these conditions. The protocol the formulation is used under is documented in Note 10.
Funding disclosure: this twelve-week efficacy study was sponsored by Core Biogenesis, the supplier of the active ingredient. The full methodology and results are published so the funding source can be weighed against the data.